Back to today’s briefing

Story perspectives

Injectable HIV Treatment Outperforms Daily Pills in Trial

3/17/2026

38 7 Full Breakdown

Summary

Story summary

The LATITUDE trial, run by the ACTG Network, shows monthly injectable HIV treatment is more effective than daily pills for adherence.
The study enrolled 453 adults and followed them for 48 weeks.
After 48 weeks, treatment failure was 22.8% with injections versus 41.2% with pills.
Researchers report no safety concerns and urge broader access to the injectable option.

1 of 1

Story summary

The LATITUDE trial, run by the ACTG Network, shows monthly injectable HIV treatment is more effective than daily pills for adherence.
The study enrolled 453 adults and followed them for 48 weeks.
After 48 weeks, treatment failure was 22.8% with injections versus 41.2% with pills.
Researchers report no safety concerns and urge broader access to the injectable option.